Curtis Ruegg, PhD

President and Chief Executive Officer

During more than 25 years in the biopharmaceutical industry, Curtis has built and managed several successful novel biologics development programs across R&D and Technical operations, from research through clinical development and commercialization. Prior to joining Parvus, Curtis was Executive Vice President, Technical Operations at Revance where he established and managed the biologics development program to support the Company’s platform from IND through Phase 3. Prior to Revance, Curtis led development efforts supporting commercialization of several products including Ventavis® (CoTherix), Esbriet® (Intermune) and Provenge® (Dendreon). Curtis earned his Ph.D. degree from Johns Hopkins University School of Medicine for work on retroviral mediated immunosuppression and worked in immunology as a Cancer Research Institute Fellow at Stanford University School of Medicine